AGP Executive Report

Military Health & Accountability: U.S. soldiers wounded in an Iranian drone strike in Kuwait say commanders underestimated the threat and that the military medical system failed them, with the Pentagon releasing few details. Public Health Threats: Russia is investigating a suspected pneumonic plague death of a lab worker in Siberia; authorities report nearly 200 close contacts under observation as EU and global health agencies watch closely. Healthcare Access & Safety: A Boston-bound medical flight from Bermuda vanished over the Atlantic; six people are presumed dead, raising questions about emergency transport safety. Responsible AI in Care: Autonomize AI joined NCQA’s AI Learning Collaborative focused on responsible use of AI for prior authorization, emphasizing governance and measurable impact. Pharma & Biotech Moves: Gland Pharma approved a $21M U.S. expansion to acquire a 60% stake in Novelstar Pharma; ARC Regulatory secured £3.7M in new lab projects with global pharma. Clinical & Treatment Updates: FDA cleared an AI tool for pediatric bone age assessments; Cordis’ SELUTION SLR drug-eluting balloon won U.S. approval for in-stent restenosis. Cancer Care Data: Experts discussed reducing false positives on prostate PSMA PET and better handling indeterminate bone lesions in imaging.

Pharma & Markets: Eli Lilly’s diabetes/obesity engine is still widening its moat, with Mounjaro and Zepbound driving most revenue growth and strong patent protection through the 2030s and beyond. Cancer Screening & Regulation: The FDA advisory panel backed GRAIL’s Galleri multi-cancer blood test, setting up a potential approval decision in the coming months. AI in Drug Discovery: At an Abu Dhabi AI event, Insilico Medicine highlighted how AI is accelerating target finding and molecule design, with some candidates moving into late-stage trials. Breast Cancer Prevention Gap: A new American Cancer Society survey finds awareness of modifiable breast cancer risk factors is high, but many women aren’t translating it into action. UTI Guidance Update: Multiple urology and infectious disease groups released recent guideline updates for urinary tract infections. Oncology Care Delivery: MUSC is piloting virtual nurse intake in ED arrival workflows to speed triage and reduce crowding. Manufacturing Capacity: Bayer plans a $2.2B Ohio manufacturing campus to expand drug substance and product output for oncology, cardiovascular, and renal care. Clinical Trial Watch: Phase 3 PROPEL is testing subcutaneous imeroprubart for generalized myasthenia gravis, with results expected to clarify dosing and patient outcomes.

Wearables & IPO Mood: Oura’s smart-ring IPO was postponed after being reported as heavily oversubscribed, underscoring how fast public-market sentiment can swing for health tech. AI for Chronic Disease: A former OpenAI exec is using AI to tackle chronic conditions, including her own POTS, via a new biotech effort. Mental Health Care Delivery: At a psychiatry conference, experts argued long-acting injectable antipsychotics can improve relapse prevention and make nonadherence visible, while AI decision tools must avoid “hallucinations” by asking missing questions first. Dementia Diagnostics: Clinicians highlighted blood-based Alzheimer biomarkers as a way to close diagnostic gaps and move beyond vague “dementia” labels. Women’s Health Access: In Idaho, abortion-rights advocates are reframing the ballot fight around doctor shortages and broader healthcare access, not just the procedure. Regulatory & Public Health Capacity: Nigeria’s NAFDAC urged partners to fund vaccine fill-and-finish manufacturing to reach WHO regulatory maturity. Clinical Care & Devices: Studies reported robotic hip/knee replacement doesn’t clearly cut repeat surgery risk overall, while rectal spacers may reduce proton-therapy toxicity in prostate cancer.

Africa Health Investment Push: Ghana President John Dramani Mahama urged African leaders to treat healthcare as an investable economic sector, calling for more funding for local pharmaceutical manufacturing, regional value chains, and health innovation to cut dependence on imported medicines and vaccines. Cancer Radiotherapy Update: New clinical discussion supports fractionated stereotactic radiosurgery after brain metastasis resection, citing improved surgical-bed control with similar radiation necrosis rates versus single-fraction approaches. Proton Therapy Safety: Research highlights how rectal spacers can reduce rectal dose and potentially lower toxicity during proton therapy for prostate cancer, with patient selection depending on tumor location. Dermatology Real-World Data: EADV reports delgocitinib cream showing real-world effectiveness in chronic hand eczema, plus additional adolescent analyses. Mental Health Care: Conference coverage spotlights covert medication nonadherence in serious mental illness and why anhedonia can signal higher suicide risk. Healthcare Access on the Ground: Niger’s private clinic was re-sealed after failing health standards, including staffing, equipment, and infection prevention gaps.

Obesity Drug Showdown: An indirect comparison links tirzepatide 15 mg to greater weight loss than semaglutide 7.2 mg in SURMOUNT-5, with GI side effects the main discontinuation driver. RSV Prevention Update: Clesrovimab is shown to remain effective and well-tolerated when repeated in infants at risk across a second RSV season. Depression Care Access: New discussion highlights accelerated TMS (SAINT) as a faster path toward remission for treatment-resistant depression, plus MRI-targeting considerations. Dermatology Pipeline: EADV coverage spotlights ritlecitinib repigmentation in nonsegmental vitiligo and deeper-control data across psoriasis/HS/AD programs. Public Health Alerts: Pennsylvania reports a fifth measles death as cases near 1,000; Nepal confirms 131 Japanese encephalitis cases with most unvaccinated. Policy & Competition: AHA backs a hospital challenge to Lilly’s 340B policy, while regulators weigh hospital consolidation and post-acute care differences in Medicare Advantage. Healthcare Ops: Kerala’s health minister denies medicine shortages in government hospitals, blaming pharma and media claims. Genomics for Kids: GeneDx rolls out “Easy Order” to simplify pediatric genomic testing workflows for AAP use.

FDA & Oncology: FDA initiated an NDA under Real-Time Oncology Review for zipalertinib plus platinum chemo in EGFR exon 20+ NSCLC, targeting a year-end 2026 completion after REZILIENT3 showed median PFS 14.5 vs 8.5 months. Hematology: FDA approved pirtobrutinib (Jaypirca) for frontline CLL/SLL in adults without 17p deletion, with BRUIN CLL-313 showing PFS not reached vs 33.5 months on bendamustine/rituximab. Drug Development & Deals: Foghorn Therapeutics and Eli Lilly halted oral SMARCA2 degrader FHD-909 after Phase I lacked antitumor activity; Novartis struck a up-to-$7.8B licensing/option deal with Abogen for mRNA-encoded T-cell engager ABO2203. Care Delivery & Access: Malawi’s CMST will prioritize locally manufactured medicines to ease shortages tied to foreign-exchange constraints. Patient Experience: A cancer monitoring platform aims to close outpatient gaps using AI symptom triage plus connected vitals. Cardio/Prevention: Smoking cessation after PAD diagnosis cut major cardiovascular and limb event risk, while reduction alone didn’t. Digital Health: Survey finds buyers will keep spending on digital health, but demand proof of member engagement.

Mental Health Access: Pakistan’s health minister says the mental health treatment gap is still about 95%, urging mental health to be built into primary care and schools. Biotech Supply Chains: U.S. lawmakers Alford and Davids introduced a bill to assess foreign biotech input vulnerabilities to strengthen domestic manufacturing. Addiction Care: A new focus on outpatient rehab highlights structured support that lets people rebuild routines at home while tracking progress. Women’s Health in Media: Organon partnered with romance novelist Hannah Brown to normalize birth control conversations through a story tied to long-acting contraception. GLP-1 Shift to Pills: An industry interview argues oral GLP-1-style options could win on convenience and adherence. Autoimmune Dealmaking: Novartis licensed Abogen’s mRNA T-cell engager ABO2203 in a deal topping $7.5B. Hospital Policy & Pricing: CMS finalized the GLOBE drug pricing model with narrower scope and smaller projected savings. Care Delivery Partnerships: South County Health joined Mayo Clinic’s Care Network, keeping local control. AI in Breast Cancer: Everlywell launched an AI risk tool using FDA-authorized mammogram analysis. Energy Pressure on Health Systems: EU governments discussed releasing diesel stocks under U.S. pressure, reflecting wider cost pressures.

Cell & Gene Manufacturing: Cellares says its rese-cel platform hit a key real-world milestone after first patient dosing, highlighting GMP buildout, FDA IND amendment clearance, and on-time release specs—while calling manufacturing scalability the biggest bottleneck. Immunology & Dermatology: Pfizer’s tilrekimig Phase 2 data in atopic dermatitis report strong EASI-75 and itch improvements; separate psoriasis coverage stresses patient-centered care beyond “clear skin.” Kidney Care: A KDIGO guideline consensus review updates lupus nephritis practice, pointing to newer options, combination regimens, and reduced steroid use. Mental Health: Research links childhood trauma to higher suicidal thoughts and attempts in adults with depression/anxiety, and a personality-based approach may refine MDD recovery prediction. Healthcare Policy & Access: The NHS rolls out a new free flu jab program for people sleeping rough, using pop-ups and mobile vans. Oncology/Drugs: FDA actions and trial updates span cardiometabolic care and cancer, including expanded Camzyos use and new pipeline progress. AI in Care: A survey finds patients are hesitant to use AI in healthcare without privacy protections and human oversight.

Biotech Shake-Up: Foghorn Therapeutics shares plunged 49% after Eli Lilly terminated their cancer collaboration, ending development of FHD-909 and a SMARCA2 program, with the company planning about 40% headcount cuts to extend cash through late 2029. Dermatology Updates: At EADV 2026, new data highlighted lebrikizumab benefits for hand-and-foot atopic dermatitis, while another study linked GLP-1 receptor agonists to a higher risk of nail detachment. Immunology Deal: Sanofi and Regeneron expanded their immunology alliance with four new long-acting antibody targets in a deal valued up to $8bn. Weight-Loss Competition: Lilly’s EloraTZP phase 2 results showed stronger weight loss than tirzepatide in adults with T2D and obesity, intensifying the incretin race. Public Health & Access: England’s flu jab eligibility expands to carers and household contacts of people with weakened immune systems, and London’s SeeAbility won an NHS contract to deliver eye care to about 70,000 SEND children. Drug Pricing Scrutiny: India’s Supreme Court is pressing for broader use of a 16% retailer margin, spotlighting large gaps between retailer prices and MRPs.

AI Policy & Data Integrity: Pennsylvania lawmakers advanced an “AI transparency” bill requiring chatbot-generated images to carry metadata so online tools can flag AI-altered content. Cybersecurity & AI Threats: The AHA urged Senate Homeland Security leaders to treat AI-enabled cyberattacks as a growing risk, especially for rural hospitals. CMS Frailty Path: CMS laid out a route for identifying and managing medical frailty, with implementation now the hard part. Sleep Apnea–Liver Link: Research ties sleep apnea to higher odds of fatty liver disease, while CPAP’s benefit appears limited to liver enzyme changes. Immunization Access: Vermont released 2026–27 flu, COVID, and RSV vaccine recommendations, including RSV guidance for infants and older adults. Medication Supply Strain: Iran faces soaring medicine prices and shortages amid US blockade and sanctions, with flu vaccine access also affected. Care Safety & Accountability: A father sued South Carolina after his autistic teen died following immobilizing restraint in a hot room, alleging state negligence. Mental Health Care Delivery: Coverage highlights metabolic psychiatry’s push to treat metabolic dysfunction as a core target, not just a side effect.

Drug Pricing Pressure in India: India’s Supreme Court questioned steep hospital mark-ups on cancer medicines, calling it “carnage” after a drug supplied at Rs 2,700 carried an MRP of Rs 27,000, and asked whether a uniform 16% margin should apply. Global Pharma Supply Strain: Iran faces soaring medicine prices—some tripling—as US blockade and sanctions disrupt imports, with pharmacy access getting harder even if hospitals haven’t yet seen major shortages. Oncology Pipeline Roundup: FDA oncology activity in September 2026 included accelerated approvals for camizestrant in ESR1-mutant breast cancer and sevabertinib in treatment-naive HER2-mutant NSCLC, plus multiple other approvals and one withdrawal. Myeloma Treatment Evolution: New expert discussions highlight how CD38-directed therapy is moving into frontline care and how clinicians are weighing bispecific antibodies versus BCMA CAR T-cell therapy, including infection and neurologic risk management. Healthcare Operations & Tech: Cold Chain Technologies launched a reusable dry ice shipper aimed at protecting ultra-low temperature shipments; drones are also being tested to speed AED delivery for out-of-hospital cardiac arrest. Workforce & Community: Parkview Health earned a Forbes/Statista workplace honor; local health groups and hospitals also announced community events and grants, including cardiac monitors via FEMA funding.

Healthcare Tariffs: A Georgia Tech/U.C. Davis study says U.S. tariffs on imported medical supplies hit $3.4B in the first half of 2025, with about 56% passed through to providers and facilities, and could jump to $15.8B in duties under later 2025 rates. Drug Pricing Policy: Public Citizen urged lawmakers to reject Germany-style pricing rollbacks in a Section 301 review, warning weaker controls would raise prices for governments and patients. FDA Biosimilars: Teva won FDA approval for Degevma, a biosimilar to Xgeva, expanding its denosumab lineup for cancer-related bone complications. Tariff Exemptions for Pharma: New U.S. Commerce guidance outlines which specialty drug categories can be exempt from 100% tariffs and how companies can pursue reduced or zero-tariff paths tied to U.S. manufacturing. Obesity/Diabetes Pipeline: Retatrutide trial results add weight-loss and improvements in knee osteoarthritis pain and sleep apnea, while experts warn against buying bootleg retatrutide online. Microbiome Testing Investment: Tiny Health raised $33M to expand gut and vaginal microbiome testing and clinical research. Care Delivery & Evidence: Australia’s Support at Home review found major gaps in proof of agreed prices, even when delivery evidence was stronger. Hospital Consolidation: Essentia Health and HealthPartners approved a merger effective Jan. 1, 2027, aiming to expand specialists and coordinated care. AI for Clinical Ops: A healthcare AI infrastructure piece argues providers must shift focus from models to the hospital systems—networking, security, and long-term workload readiness.

Drug Pricing & Access: India’s Supreme Court called steep hospital markups on cancer medicines “carnage,” questioning why a 16% margin under the DPCO isn’t applied more uniformly and flagging a near 10x gap between retailer price and MRP. AI in Imaging: Sweden’s Stockholm Region plans to replace radiologist “second reads” for breast screening with AI-assisted mammography at regional scale, following earlier rollouts. Gene Therapy Milestone: The FDA approved Fayuvi, the first US gene therapy for Sanfilippo syndrome type A, using a one-time AAV9 infusion in children with preserved neurodevelopment. Rare Disease Pipeline: Mirum reported late-stage results for brelovitug in chronic hepatitis D, aiming to compete with Hepcludex as viral suppression and liver enzyme normalization were met. Neuro/Behavioral Care: Panels highlighted adult ADHD’s real-world burden and schizophrenia care gaps, including when to switch treatments and how adherence and metabolic risk shape decisions. Healthcare Operations & Tech: Prenuvo announced a new research network to expand evidence from its whole-body MRI scans; Harrison.ai cut staff ~15% while reporting revenue growth. Policy & Markets: The US exempted India and others from 100% tariffs on select speciality drugs, while experts warned new tariff rules could hit smaller pharma hardest.

Schizophrenia Care: Experts argue negative and cognitive symptoms are often missed in routine visits, pushing for measurement-based care and better caregiver tracking to define what “stable” really means. ADHD Diagnosis: New coverage highlights adult ADHD underdiagnosis—especially when anxiety or depression comes first—and why earlier, accurate diagnosis can improve long-term outcomes. Psychiatry Treatment Access: Clinicians urge moving to interventional options sooner in treatment-resistant depression, weighing TMS and esketamine against practical barriers like contraindications and insurance timing. Suicide Prevention: Reviews focus on evidence-based pharmacologic approaches and emerging endocrine biomarkers to better predict suicide risk in schizophrenia. Substance Use Disorder Tech: The FDA granted Breakthrough Device Designation to NET Recovery’s device for stimulant use disorder, aiming to reduce psychostimulant use without drugs. Diabetes Tech: DreaMed won FDA 510(k) clearance for CGM-driven insulin automation for people using both basal and mealtime injections. Pharma Deals & Policy: Merck licensed SciBrunch’s preclinical KRAS G12D inhibitor in a deal up to $2.13B, while a Kerala court signaled the government can intervene on exorbitantly priced patented drugs. Healthcare Business: Coverage examines how private equity hospital ownership is reshaping care delivery and costs.

Health Insurance Strain: A new report shows even healthcare workers are dropping coverage as premiums climb, with one family medicine practice now uninsured after ACA marketplace credits ended. Policy & Access: California’s governor race spotlights competing plans for affordability and coverage, while MGMA warns Medicaid work requirements and CMS remote monitoring changes could reshape RPM/RTM billing starting Jan. 1, 2027. Cardiac Care Updates: A clinician explains when coronary angiography should be considered for accurate CAD diagnosis, and another piece argues valve care success depends on what happens after surgery—not just the procedure. Digital Health & AI Governance: Digital twins are moving into clinical trials, but data limits and regulation remain barriers; meanwhile, AI governance for hospitals and insurers is at a crossroads. Oncology & Imaging: PSMA PET use is expanding in prostate cancer, with panels also flagging radiotracer access and reimbursement friction. Women’s Health & Substance Use: Gender-responsive care is urged for substance use disorder, where women face faster progression and different treatment needs. Weight-Loss Safety: Enforcement data shows a surge in fake GLP-1 listings, raising risks from unprescribed and counterfeit products. FDA/Drug Pipeline: FDA approvals include Mirum’s oral drug for rare FOP and Lilly’s once-weekly insulin Onswik, plus new oncology combo approvals. Community Health: Behavioral Health Network begins operations in Worcester, expanding mental health and substance use services.

ACA Crackdown: The Trump administration canceled coverage for about 760,000 people on ACA Marketplace plans, citing “fraud” or that enrollees “do not exist,” while also freezing new agent/broker registrations for 2027 open enrollment. Dementia Support: Curtin University launched Brain Health WA, a free, co-designed resource aimed at translating dementia risk-reduction science into practical, culturally relevant actions and local support. Cancer Care Updates: At the IMS meeting, community-focused guidance highlighted a “functional cure” approach in multiple myeloma using MRD and imaging; separate research points to improved patient experience with subcutaneous isatuximab via an on-body injector and promising PFS projections for isatuximab-based regimens. Oncology Treatment Strategy: New discussion supports shifting radiation to the neoadjuvant setting for borderline resectable or locally advanced cholangiocarcinoma to improve tolerability and resection chances. Diabetes Innovation: The FDA’s approval of once-weekly insulin efsitora alfa-gobe adds a second product to the weekly basal class, with distinct dosing and titration guidance. Public Health Watch: CDC updates continue on overlapping Salmonella and E. coli outbreaks tied to sprouts, jalapeño peppers, and pet turtles. Food & Nutrition: A trial found that cutting sweet-tasting foods for six months didn’t meaningfully change sweet preference or measured cardiometabolic markers. Workforce & Access: Reports say some healthcare workers are dropping health insurance due to rising costs, raising concerns about delayed care and added strain on systems.